Belvin Marcia's most recent trade in CytomX Therapeutics Inc was a trade of 37,500 Common Stock done . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 37,500 | 286,136 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2025 | 37,500 | 0 | - | - | Performance Stock Units | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.69 per share. | 13 Jun 2025 | 13,884 | 272,252 (0%) | 0% | 2.7 | 37,334 | Common Stock |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.60 per share. | 18 Mar 2025 | 19,512 | 248,636 (0%) | 0% | 0.6 | 11,688 | Common Stock |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 57,500 | 263,148 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 57,500 | 268,148 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 35,000 | 210,648 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 30,000 | 205,648 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | 20 Aug 2024 | 11,250 | 179,829 (0%) | 0% | 0 | Common Stock | ||
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | 20 Aug 2024 | 11,250 | 0 | - | - | Performance Stock Units (PSUs) | ||
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | 20 Aug 2024 | 4,181 | 175,648 (0%) | 0% | 1.2 | 5,139 | Common Stock | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | 19 Mar 2024 | 12,795 | 168,579 (0%) | 0% | 2.1 | 26,684 | Common Stock | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | 18 Jan 2024 | 122,500 | 122,500 | - | - | Stock Option (Right to Buy) | ||
| CytomX Therapeutics Inc | Belvin Marcia | SVP, Chief Scientific Officer | 18 Jan 2024 | 75,000 | 75,000 | - | - | Performance Stock Units (PSUs) | ||
| CytomX Therapeutics Inc | Belvin Marcia | SVP, Chief Scientific Officer | 18 Jan 2024 | 26,250 | 181,374 (0%) | 0% | 0 | Common Stock | ||
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | 20 Dec 2023 | 4,077 | 155,124 (0%) | 0% | 1.4 | 5,628 | Common Stock | |
| CytomX Therapeutics Inc | Belvin Marcia | SVP, Chief Scientific Officer | 17 Dec 2023 | 11,250 | 159,201 (0%) | 0% | 0 | Common Stock | ||
| CytomX Therapeutics Inc | Belvin Marcia | SVP, Chief Scientific Officer | 17 Dec 2023 | 11,250 | 11,250 | - | - | Performance Stock Units (PSUs) | ||
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | 20 Sep 2023 | 11,250 | 152,070 (0%) | 0% | 0 | Common Stock | ||
| CytomX Therapeutics Inc | Belvin Marcia | SVP, Chief Scientific Officer | 20 Sep 2023 | 4,119 | 147,951 (0%) | 0% | 1.3 | 5,356 | Common Stock | |
| CytomX Therapeutics Inc | Marcia Belvin | SVP, Chief Scientific Officer | 22 Mar 2023 | 60,000 | 140,820 (0%) | 0% | 0 | Common Stock |